Appia Bio is a preclinical stage biotech company founded in 2020 with the mission to bring innovative off-the-shelf cell therapies to cancer patients. Our novel platform can generate a broad array of allogeneic NKT and T cell types and can be engineered to address challenges in tumor microenvironments. Our goal is to discover and develop allogeneic cell therapies across a broad array of cancer indications with a scalability that increases access for patients.
